Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 41.00
+0.30 (0.74%)
Apr 17, 2026, 1:30 PM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 10.86 billion as of April 17, 2026. Its market cap has decreased by -37.11% in one year.
Market Cap
10.86B
Enterprise Value
11.56B
Revenue
400.97M
Ranking
n/a
PE Ratio
n/a
Stock Price
41.00
Market Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 10.86B, a decrease of -35.25%. That is a compound annual growth rate of -3.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2026 | 10.86B | -25.44% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Polaris Group | 16.17B |
| Medigen Vaccine Biologics | 15.78B |
| EirGenix | 15.31B |
| TaiMed Biologics | 14.56B |
| Ever Supreme Bio Technology | 12.26B |
| CHO Pharma | 11.56B |
| Locus Cell | 10.22B |
| PharmaEngine | 8.46B |